Pulmonary hypertension, often known as PH, is a disorder in which blood pressure rises in the pulmonary artery, vein, or capillaries (together known as lung vasculature), causing shortness of breath, fainting, leg edoema, and dizziness, among other symptoms. Pulmonary hypertension is a persistent condition that causes a significant decline in exercise tolerance. The term pulmonary arterial hypertension, or PAH, refers to a patient's excessive blood pressure in the arteries that deliver blood from the heart to the lungs. PAH causes the arteries in the lungs to narrow or get clogged, resulting in erratic blood flow.Because the flow of blood is obstructed, it becomes difficult for the blood to flow uniformly, raising the patient's blood pressure. In layman's words, this implies the heart has to work harder to pump blood. After a specific period of time, it may cause weakening of the cardiac muscles. Pneumoarterial hypertension can eventually lead to heart failure.
According to reports from many sources, including the CDC (Centers for Disease Control and Prevention) and the WHO (World Health Organization), the global prevalence of pulmonary arterial hypertension market is estimated to be 100,000 – 200,000, or around 15 – 50 individuals per million of the population. Despite the fact that treatment for pulmonary arterial hypertension market is limited, there are a variety of treatment options available to reduce symptoms, delay disease progression, and enhance quality of life. Endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and Prostacyclin and prostacyclin analogues are among the most commonly prescribed pharmacological groups used to treat the disease. Recently, a new medication class called as soluble guanylate cyclase (sGC) stimulators has been shown to be successful in the treatment of PAH patients.
On the contrary, the patent expiration of important pulmonary arterial hypertension market medications such as Letairis, Tracleer, Tyvaso, and Adcirca is expected to offer a threat to market growth, as generic copies of these drugs will be sold at 70% to 80% less than the current branded drugs. Various breakthrough therapies for the treatment of pulmonary arterial hypertension are expected to be a growth factor for PAH treatment drug producers, as the present drugs are insufficient to address the needs of the patients. These factors will drive the PAH market forward and raise demand for PAH treatment medications.
Some of the major companies operating in the pulmonary arterial hypertension (PAH) market in the current scenario are Actelion Pharmaceuticals, Ltd., Gilead Sciences, Inc., United Therapeutics Corporation, Bayer HealthCare, Pfizer, Inc., Novartis International AG and GlaxoSmithKline plc.
No comments:
Post a Comment